Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company focused on chronic low back pain, today published a shareholder letter from CEO Brent Ness highlighting the company's recent momentum and value-creating priorities for 2026. The letter, available on the company's website, underscores Aclarion's disciplined execution toward key catalysts that aim to expand adoption of its Nociscan platform and strengthen its clinical and reimbursement foundation.
Among the most significant initiatives is the pursuit of reimbursement coverage from one or more regional insurance providers in the United States. This step is considered critical for broader payer adoption and follows the company's ongoing reimbursement efforts in the United Kingdom. Securing such coverage would enable more patients to access Nociscan, a noninvasive SaaS platform that helps physicians identify painful discs in the lumbar spine using magnetic resonance spectroscopy (MRS) data and proprietary augmented intelligence algorithms.
Another major catalyst highlighted is the initial readout of the CLARITY clinical trial, expected in Q4 2026. This trial is designed to provide further clinical evidence supporting Nociscan's efficacy in distinguishing painful from nonpainful discs. The results are anticipated to bolster the company's value proposition to physicians, imaging centers, and payers. Aclarion has reported increasing physician engagement and commercial activity, with expansion of its network of imaging centers using the platform.
The company also emphasized its strong balance sheet, with a cash runway extending into 2028. This financial position allows Aclarion to continue executing its strategic plan without near-term funding pressures. CEO Brent Ness stated that the focus remains on disciplined execution against key catalysts that can expand Nociscan adoption and strengthen the clinical and reimbursement foundation. He expressed confidence that Aclarion is well positioned to advance its mission of building a scalable technology platform for chronic low back pain while creating long-term value for patients and shareholders.
For more information on Aclarion and its Nociscan platform, visit the company's website. The latest news and updates relating to $ACON are available in the company's newsroom at https://tinyurl.com/aconnewsroom.
